Parallel, AA/BB, AB/BA and Balaam's design: Efficient and maximin choices when testing the treatment effect in a mixed effects linear regression

Pharmaceutical Statistics

Volumn 11, Issue 2, 2012, Pages 97-106

  Candel, Math J J M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

(extended) parallel design; AB BA cross over design; Balaam's design; efficient design; maximin design

Indexed keywords

ARTICLE; BALAAM DESIGN; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; LINEAR REGRESSION ANALYSIS; PARALLEL DESIGN; STATISTICAL MODEL; STUDY DESIGN; VARIANCE;

CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; CROSS-OVER STUDIES; HUMANS; LINEAR MODELS; MODELS, STATISTICAL; PATIENT DROPOUTS; RESEARCH DESIGN;

EID: 84858440524     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.502     Document Type: Article

References (22)

1. Jones B, Kenward MG,. Design and analysis of cross-over trials. Chapman & Hall: London, 1989.
2. Senn S,. cross-over Trials in Clinical Research. Wiley: Chichester, 2002.
3. Brown H, Prescott R,. Applied Mixed Models in Medicine. Wiley: Chichester, 2006.
4. Berger MPF, Wong WK,. An Introduction to Optimal Designs for Social and Biomedical Research. Wiley: Chichester, 2009.
5. Atkinson AC, Donev AN, Tobias RD,. Optimum Experimental Designs, with SAS. Oxford university press: Oxford, 2007.
6. Low JL, Lewis SM, Prescott P,. Assessing robustness of crossover designs to subjects dropping out. Statistics and Computing 1999; 9: 219-227.
7. Grizzle JE,. The two-period change over design in clinical trials. Biometrics 1965; 21: 467-480.
8. Freeman P,. The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Statistics in Medicine 1989; 8: 1421-1432. (Pubitemid 20071040)
9. Liang Y, Carriere KC,. On the role of baseline measurements for crossover designs under the self and mixed carryover effects model. Biometrics 2010; 66: 140-148.
10. Putt ME,. Power to detect clinically relevant carry-over in a series of cross-over studies. Statistics in Medicine 2006; 25: 2567-2586. (Pubitemid 44082447)
11. Jones B, Donev AN,. Modelling and design of cross-over trials. Statistics in Medicine 1996; 15: 1433-1446.
12. Senn S, Lambrou D,. Robust and realistic approaches to carry-over. Statistics in Medicine 1998; 17: 2849-2864. (Pubitemid 28562980)
13. Fleiss JL,. A critique of recent research on the two-treatment cross-over design. Controlled Clinical Trials 1989; 10: 237-243. (Pubitemid 20014082)
14. Senn S,. cross-over trials in drug development: theory and practice. Journal of Statistical Planning and Inference 2001; 96: 29-40. (Pubitemid 33619417)
15. Garcia R, Benet M, Arnau C, Cobo E,. Efficiency of the cross-over design: An empirical evaluation. Statistics in Medicine 2004; 23: 3773-3780. (Pubitemid 40074076)
16. Kenward MG, Roger JH,. The use of baseline covariates in crossover studies. Biostatistics 2010; 11: 1-17.
17. Lasserre V,. Determination of optimal designs using linear models in crossover trials. Statistics in Medicine 1991; 10: 909-924.
18. Yuan Y, Zhou J,. Cost-efficient higher-order crossover designs for two-treatment clinical trials. Pharmaceutical Statistics 2005; 4: 245-252. (Pubitemid 43013599)
19. Brown BW Jr,. The crossover experiment for clinical trials. Biometrics 1980; 36: 69-79.
20. Spiegelhalter DJ, Abrams KR, Myles JP,. Bayesian approaches to clinical trials and health-care evaluation. Wiley: Chichester, 2007.
21. Miner PB Jr, McKean LA, Gibb RB, Erasalu GN, Ramsey DL, MCrorie JW,. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses. Alimentary Pharmacology & Therapeutics 2010; 31: 846-851.
22. Senn S,. cross-over trials in Statistics in Medicine: The first 25 years. Statistics in Medicine 2006; 25: 3430-3442. (Pubitemid 44575161)